SRR1341898
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.566
- ANGIOGENESIS+0.493
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.471
- INFLAMMATORY_RESPONSE+0.468
- IL6_JAK_STAT3_SIGNALING+0.410
- COAGULATION+0.384
- INTERFERON_ALPHA_RESPONSE+0.371
- APOPTOSIS+0.369
- INTERFERON_GAMMA_RESPONSE+0.354
- CHOLESTEROL_HOMEOSTASIS+0.328
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.546
- MYC_TARGETS_V2-0.471
- DNA_REPAIR-0.434
- MYC_TARGETS_V1-0.420
- PROTEIN_SECRETION-0.380
- UNFOLDED_PROTEIN_RESPONSE-0.358
- PI3K_AKT_MTOR_SIGNALING-0.320
- E2F_TARGETS-0.319
- G2M_CHECKPOINT-0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.233
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1465632 | GTEX | — | 0.952 |
| 2 | SRR1435901 | GTEX | — | 0.935 |
| 3 | SRR1329885 | GTEX | — | 0.931 |
| 4 | SRR1444932 | GTEX | — | 0.931 |
| 5 | SRR1384030 | GTEX | — | 0.930 |
| 6 | SRR1093773 | GTEX | — | 0.920 |
| 7 | SRR1440082 | GTEX | — | 0.918 |
| 8 | BS_ZTWGFWTX | pilocytic astrocytoma | — | 0.918 |
| 9 | SRR1084484 | GTEX | — | 0.914 |
| 10 | SRR1470111 | GTEX | — | 0.913 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.566 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.493 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.471 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.468 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| COAGULATION | 0.384 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.371 | Inavolisib | — uncovered |
| APOPTOSIS | 0.369 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.354 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.328 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.326 | Idelalisib | — uncovered |
| HYPOXIA | 0.308 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.308 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.294 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.293 | Inavolisib | — uncovered |
| COMPLEMENT | 0.279 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.277 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.260 | Idelalisib | — uncovered |
| MYOGENESIS | 0.254 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.246 | Idelalisib | — uncovered |